In GBM, LMTK2 mediates tumor suppression by upregulating RUNX3, which in turn inhibits the Notch signaling pathway; low levels of LMTK2 are associated with poor overall survival, thereby suggesting that both LMTK2 and RUNX3 collectively influence the prognosis of GBM patients [116]. Here, LMTK2 is linked to glioblastoma.